Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, announced today that the ...

REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech ... today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic ...

MAIA Biotechnology, Inc., (NYSE American ... a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking ...

NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentationPRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune ...

Poster highlights potential predictive biomarker ... of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused ...